New Delhi, Oct 17 (PTI) Biocon Biologics on Monday said it has inked an out-licensing agreement with Yoshindo Inc to commercialise its two biosimilar assets in the Japanese market.

Under the terms of this deal, Japan-based Yoshindo gets exclusive commercialisation rights in Japan for Ustekinumab and Denosumab -- developed and manufactured by Biocon Biologics -- for an addressable market opportunity of USD 700 million, Biocon Biologics said in a statement.

Also Read | Apple To Reportedly Launch macOS Ventura Later This Month.

Biocon Biologics, a unit of Biocon, will receive an upfront license fee as well as additional payments on the achievement of certain development milestones over the next few years.

Ustekinumab biosimilar is a monoclonal antibody used to treat several autoimmune conditions, including psoriasis, Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.

Also Read | iQOO Neo 7 5G Specifications Confirmed Ahead of Its Launch.

Denosumab is a monoclonal antibody for the treatment of osteoporosis.

"Once approved, these products will expand our offering of affordable, high-quality biosimilars in the Japanese market and help address unmet patient needs in bone health and immunology therapy areas," Biocon Biologics Deputy Chief Executive Officer Shreehas Tambe said.

The company is developing a broad portfolio of 20 biosimilar assets either independently or through strategic partnerships.

Biocon Biologics became the first company from India to commercialise a biosimilar in Japan after its Insulin Glargine was successfully launched in Japan by another partner in 2016.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)